Post-intrathecal chemotherapy-related paraplegia syndrome in hematological cancer patients: A systematic review

• Published in: Neuro-oncology advances 2025-01, Vol.7 (1), p.vdae217
• Main Authors: Monnikhof, Matthijs, Hamming, Gabriella, Crnko, Sandra, Brandsma, Rick, van Rhenen, Anna, Monnikhof, Thomas, Bovenschen, Niels, Kaspers, Gertjan, Flinsenberg, Thijs W H
• Format: Article
• Language: English
• Subjects: Meta-analysis/Systematic Review
• ISSN: 2632-2498; 2632-2498
• DOI: 10.1093/noajnl/vdae217

Intrathecal (IT) chemotherapy is essential in treating hematological malignancies, but it can lead to ascending paraplegia, a condition that currently lacks clear management guidelines. We conducted a systematic review, analyzing 1219 studies and 116 patients, adhering to PRISMA guidelines for individual patient data. The study, registered under PROSPERO (CRD42022362121), focused on the onset, diagnostic approaches, and therapeutic interventions associated with this complication, and management strategies to tackle the ascending paraplegia. Paraplegia typically manifests approximately 10 days after chemotherapy, irrespective of injection frequency. In 95% of cases, paralysis stabilizes around the umbilical region, although some patients progress to upper limb involvement and respiratory compromise. Despite various diagnostic methods, consistent inflammatory markers in blood or cerebrospinal fluid are lacking, with approximately 60% of patients showing normal magnetic resonance imaging results at presentation. Misdiagnoses often include transverse myelitis, Guillain-Barré syndrome, and autoimmune radiculitis. Common treatments such as corticosteroids and intravenous immunoglobulins show limited effectiveness. Our review delineates the clinical entity of ascending paraplegia following IT chemotherapy, aiming to increase clinician awareness and provide prognostic insight. We introduce the term post-IT paraplegia syndrome to facilitate accurate diagnosis and optimize treatment strategies for affected patients.